908 Devices Expands Narcotics Detection with $15M NIRLAB Acquisition
Event summary
- 908 Devices acquired NIRLAB AG for $15M ($13M cash, $2M stock) with up to $8M more contingent on performance milestones.
- NIRLAB’s AI-powered, cloud-connected NIR spectroscopy handheld device analyzes over 400 drugs in seconds, including purity and cannabis content.
- The acquisition strengthens 908 Devices’ law enforcement portfolio, combining NIRLAB’s technology with its existing chemical analysis solutions.
- NIRLAB, founded in 2021 as a University of Lausanne spin-out, has 15 employees and has conducted over one million field analyses.
The big picture
The acquisition positions 908 Devices as a leader in handheld chemical analysis for law enforcement, addressing the growing need for rapid, accurate narcotics detection. The deal reflects a broader trend of consolidation in the forensic technology sector, where companies are integrating AI and cloud connectivity to enhance field-based chemical identification. With NIRLAB’s proven technology and 908 Devices’ commercial infrastructure, the combined entity aims to better serve law enforcement agencies worldwide.
What we're watching
- Integration Execution
- How 908 Devices will merge NIRLAB’s technology with its existing portfolio to create a seamless workflow for law enforcement.
- Market Expansion
- Whether the acquisition will accelerate 908 Devices’ global reach in narcotics detection, particularly in regions with high illicit drug activity.
- Performance Milestones
- The pace at which NIRLAB meets the contingent performance milestones to unlock the additional $8M in stock.
Related topics